Abstract
device related infection secondary to an infected toenail which was remote to the time of implantation. Four recurrent cerebrovascular events were reported with a median time to event of 29 months. The only independent predictor of a recurrent event was a history of diabetes mellitus (p= 0.03). No recurrent decompression illness was reported. 90.3% of patients with history of migraine reported either resolution or improvement in their symptoms. Multi-regression analysis revealed that the only significant predictor of improvement or resolution inmigraine symptomswasahistoryof associatedaura (p= 0.007). Conclusion: Percutaneous device closure is an effective and safe therapy for PFO complicated by paradoxical embolism, decompression illness andmigraine with aura. doi:10.1016/j.hlc.2009.05.550
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
